The Next Phase: FDA Looks Beyond Three-Stage Drug Development Model
Executive Summary
The move towards mechanism-based therapies may call for clinical development programs that diverge from the traditional three-phase regime, FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said
You may also be interested in...
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion
Adaptive Trials Going Mainstream With Industry White Paper, FDA Guidance
Adaptive clinical trials in drug development are moving towards broader acceptance and feasibility with the upcoming publication of an industry white paper and an FDA workshop on the subject